Company

TVAX Immunotherapy®

TVI-Brain-1

Pipeline

Patient Resources

News

TVAX Biomedical in the News

Stay informed with the latest updates and developments from TVAX Biomedical. This collection of select news articles and press releases reflect the company’s progress and impact in the cancer therapeutics industry.

June 1, 2026

American Society of Clinical Oncology

TVAX Biomedical Poster “Initial Analysis of Adoptive Neoantigen-Specific Immunotherapy for MGMT-Unmethylated (TVI-AST-008) Glioblastoma: Promising Survival Results” is presented at 2026 ASCO Annual Meeting by Dr. Tolga Tuncer, University of Kansas Health System.

Copyright credit: ©2026 American Society of Clinical Oncology. Reproduced with permission. Presented at the ASCO Annual Meeting, June 2026, Chicago, IL.

View

September 23, 2025

Company News

Promising New Data Demonstrates Chemo-Immunotherapy Treatment Approach with ECI® Significantly Improves Outcomes in Dogs with Bone Cancer

View

June 2, 2025

American Society of Clinical Oncology

TVAX Biomedical Poster “A novel cellular immunotherapy using vaccine generated neoantigen-specific effector T cells” is presented at 2025 ASCO Annual Meeting by Dr. Tolga Tuncer, University of Kansas Health System.

Copyright credit: ©2025 American Society of Clinical Oncology. Reproduced with permission. Presented at the ASCO Annual Meeting, June 2025, Chicago, IL.

View

March 19, 2025

Company News

ELIAS Animal Health Receives Approval from USDA for the ELIAS Cancer Immunotherapy (ECI®), First-In-Class Treatment for Canine Osteosarcoma

View

June 29, 2023

BioSpace

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

View

October 18, 2022

Company News

TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study

View

August 2, 2022

Company News

ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy

View

April 30, 2020

Company News

TVAX Biomedical Receives Fast Track Designation from the FDA

View

March 11, 2019

Company News

TVAX Biomedical Names Wayne Carter as President and CEO

View

October 25, 2018

Company News

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

View

April 6, 2015

Fierce Pharma

TVAX pours $2M funding round into canine osteosarcoma drug

View
Scroll to Top